Urmila Aswar, profile picture
Uploaded byUrmila Aswar
PPTX, PDF25,469 views

Regulatory agencies

The document discusses regulations for clinical trials in India. It begins by explaining that an Investigational New Drug Application (IND) provides an exemption that allows investigational drugs to be transported across state lines for clinical trials. It then describes the process of submitting an IND to the FDA, including providing animal studies data, manufacturing information, clinical protocols, and investigator information. It notes that the FDA has 30 days to review submitted INDs. Finally, it summarizes that in India, an application for clinical trials should be submitted to the DCGI along with chemistry, manufacturing, animal study data and other required documents and trial protocols, and trials can only begin after approval from the DCGI and ethics committee.

Embed presentation

Downloaded 908 times
Clinical Trials regulations Dr Urmila M. Aswar Department of Pharmacology, SIOP, Narhe
Investigational New Drug Application • Current Federal law requires that a drug be approved for marketing application before it is transported or distributed across state lines. • But in case of investigational drug, it is required by clinical investigators in many states. • IND is an exemption.
• FDA's role in the development of a new drug begins when the drug's sponsor (usually the manufacturer or potential marketer) having screened the new molecule for pharmacological activity and acute toxicity potential in animals, wants to test its diagnostic or therapeutic potential in humans. At that point, the molecule changes in legal status under the Federal Food, Drug, and Cosmetic Act and becomes a new drug subject to specific requirements of the drug regulatory system.
Animal Pharmacology and Toxicology Studies
Manufacturing Information Composition, manufacturer, stability, and controls used for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug. Lic form-29 is taken for mfg of new drug
Clinical Protocols and Investigator Information • Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. • Information on the qualifications of clinical trial team. • Informed consent from the research subjects, • to obtain review of the study by an institutional review board (IRB), • Adherence to the investigational new drug regulations.
Review by FDA • Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA (DCGI/CDSCO) has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.
Summary • An application to conduct clinical trials in India should be submitted along with the data of chemistry, manufacturing, control and animal studies to DCGI. The date regarding the trial protocol, investigator's brochures, and informed consent documents should also be attached. A copy of the application must be submitted to the ethical committee and the clinical trials are conducted only after approval of DCGI and ethical committee. To determine the maximum tolerated dose in humans, adverse reactions, etc.
New Drug Application • The new drug registration (using form no. 44 along with full pre-clinical and clinical testing information) is applied after the completion of clinical trials. • The comprehensive information on the marketing status of the drug in other countries is also required other than the information on safety and efficacy. • The information regarding the prescription, samples and testing protocols, product monograph, labels, and cartons must also be submitted. • Schedule Y of D&C act, provides the guidelines and requirements for clinical trials. • The application can be reviewed in a range of about 12- 18 months
Regulatory bodies in World • USA: FDA, Dept of health and human services • Canada: Health Canada • UK: Medicines and Healthcare products regulatory agency (MHRA) • EU: European Medicines Agency (EMEA) • Japan: Pharmaceutical and Medical Devices agencies (PMDA) • India:
Regulating bodies in India • The Drug and Cosmetic Act 1940 and Rules 1945 were passed by the India's parliament to regulate the import, manufacture, distribution and sale of drugs and cosmetics. • The Central Drugs Standard Control Organization (CDSCO), • The Drugs Controller General (India) [DCGI] was established.
NDA
Regulatory requirements for clinical trials Before starting trial • Consent of investigator • Approval by IRB..approval of protocol, site, • Approval from ICMR in case of new molecules developed in India • Informed consent • Insurance cover for trial related injury
During the conduct • Compliance with the trial protocol • Reporting protocol violations to EC • Seek approval for protocol amendments • Adherence to GCP • Record all adverse effects • Record of all serious adverse effects to sponsor in 24 hr • Notification of fatal adv effect to RB • Review the progress of results of study • Send periodic status of study.
Post trial requirement • Site close out • Check investigational product utilization • Analyze the data using statistical softwares • Forward the report from investigator to EC • Seek new drug approval. • Prepare and submit the prescribing information for ND to the authorities
Newly approved drugs • Gilotrif (afatinib) Tablets: for lung cancer Boehringer Ingelheim Pharmaceuticals • Khedezla (desvenlafaxine): for depression Osmotica Pharmaceutical Corp.
REGULATORY BODIES
Regulations: Actually not new
• Clinical trials: World wide • Follow ICH/WHO, GCP provides universal standards • US, Canada, EU, Japan, Australia and India
USFDA: Achievements in Clinical Research (1975-2000) • Ethical Principles and Infrastructure (IRBs) • Evidence-Based Decision-Making – Safety; Efficacy • Standards of Research Conduct (GCP) • International Harmonization • Quality Improvement
Why so much strict: A Change in Clinical Trials • More clinical investigators • More studies • More participation of vulnerable populations – Children, Elderly, Ethnic Groups, etc. • More “outsourcing” (CRO’s, SMO’s) • New technologies • Global expansion – Countries/areas new to GCP
CT Disasters in history: A lesson • May 1999: NY Times, “Research for Hire. A Doctor’s Drug Studies Turn into Fraud” • September 1999: Death in gene therapy trial • December 2000: Washington Post series “The Body Hunters” • June 2001: Death in lung physiology trial
FDA’s Mission • FDA has a broad public protection mission Ensure the safe use of regulated products that are themselves safe and efficacious Approvals: Based on complete and accurate information from well-designed, ethically- conducted, and well-monitored clinical research
FDA’s Mission in Clinical Research • Ensure Implementation of Good Clinical Practice (GCP) Standards – GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects – GCP embraces trial objectives, trial design, study oversight, data collection and quality assurance, study analysis, as well as human subject protection in studies that support product applications
Good Clinical Practice • GCP is most fundamentally a System of Shared Responsibilities –Clinical Investigators –Institutions/Institutional Review Boards –Industry (Sponsors/Monitors) –Government Regulators
FDA: Regulations • Federal food, drug and cosmetic act, 1938 • Orphan drug act 1983, • Prescription drug user fee act, 1992 (PDUFA). • Food and drug modernization act 1997, (FDAMA)
3 approaches for treating serious diseases • Fast track: to get important new drug to the patient ealier. • For no therapy/ superior new drug. • Accelerated approval: allows earlier approvals of drugs to treat serious diseases or fills an unmet medical need based on a surrogate endpoint. • S.endpoint means a lab test or a physical sign or survival. • Post marketing trials become important. • Continue or remove • Priority review: the drugs that offer major advantage in the treatment or provide a treatment where no adequate therapy exists. • Review time is reduced.
Federal food, drug and cosmetic act, 1938 • Basic food and drug law in the US • Food are pure and safe to eat • Drugs and devices are safe to use • Cosmetics are safe and made from appropriate ingredients.
Code for federal regulations (CFR) • The CFR is divided into 50 titles • SECTION 21 OF CFR –regulations related to food and drugs. • Part of CFR 21 give details of IND (312), NDA (314), orphan drugs (316)
Center for Biologics Evaluation and Research (CBER) • Section 505 of FD & C provide that no person can market a drug without filling IND. • Dept of health and human services of FDA protects the rights of human in Clinical Trial. • The CBER is one of six main centers for the U.S. Food and Drug Administration, which is a part of the U.S. Department of Health and Human Services. • CBER is responsible for assuring the safety, purity, potency, and effectiveness of biologics and related products (such as vaccines live biotherapeutics (probiotics), blood products, and cell, tissue, and gene therapies).
Center for Drugs Evaluation and Research (CDER) • The center reviews applications for new and generic pharmaceuticals, manages US current Good Manufacturing Practice (cGMP) regulations for pharmaceutical manufacturing, determines which medications require a medical prescription, monitors advertising of approved medications, and collects and analyzes safety data about pharmaceuticals that are already on the market. • CDER reviews New Drug Applications to ensure that the drugs are safe and effective. Its primary objective is to ensure that all prescription and OTC medications are safe and effective when used as directed.
Bioresearch Monitoring Program • FDA's Bioresearch Monitoring (BIMO) program is a comprehensive program of on-site inspections and data audits designed to monitor all aspects of the conduct and reporting of FDA regulated research. • It assure the quality and integrity of data submitted to the agency in support of new product approvals. • It provide for protection of the rights and welfare of the thousands of human subjects involved in FDA regulated research. • It has become a cornerstone of the FDA preapproval process for new medicines, medical devices, food and color additives and veterinary products introduced to the U.S. consumer.
• Post Ranbaxy, Wockhardt faces a hit as US FDA bans imports over quality concerns ET Bureau May 24, 2013 • The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS)
Regulations-UK/EU • Drugs are licensed for use in the UK with a European license or a national license. They are licensed through European Medicines Agency (EMEA) for Europe wide license and from Medicine and healthcare products regulatory agency (MHRA) for UK license. EMEA, Committee for orphan medicinal products (COMP): orphan drugs: 5/10,000
Centralized system in EMEA • Drugs for AIDS • NEURODEGENRATIVE DISEASES • CANCER • DIABETES • ORPHAN DRUGS
Decentralized system in EMEA • Other than the listed • Apply for more than one country of EU • With review of 1 country can be licensed in other.
• Prior to 2004 the standards were guidelines and dual standards existed • For the first time ethical and scientific standards for the set up, and conduct of clinical research involving human subjects receiving investigational medicinal products, became subject to law CLINICAL TRIAL REGULATIONS
• EU Directives are legislation issued by the European Union defining an outcome or change that is binding for each member state • EU Directives must be transposed into law for each member state to become law in that country • In the UK this is achieved by the introduction of a Statutory Instrument named within an Act of Parliament, which then becomes the law European Directives & UK Laws
EU Clinical Trials Directive 2001/20/EC EU GCP Directive 2005/28/EC EU Legislation UK Legislation Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 1031) Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (SI 1928) Amendment 2006 (SI 2964) Amendment 2008 (SI 941) Amendment 2009 (SI 1164) ‘Guidance’ EC Commission Eudralex – Volume 10 Clinical Trial guidelines ICH GCP Topic E6 – Good Clinical Practice Organisation/Sponsor SOPs Research Governance Framework for Health and Social Care • Amendment 2010 (SI 1882)
• Introduced to ensure that everyone follows the same GCP standards • Clarified and standardised practice for the safety of the subject and the quality of the data. • Major areas of change included: • - The ethics review system came under the law • - Each member state had to appoint a Competent Authority (MHRA in UK) • - Strengthened consent for vulnerable groups • - Amendments required to follow a process • - Additional safety reporting requirements • - All results have to be made available even if negative findings were found European Clinical Trials Directive 2001/20/EC
GCP principles are a standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are protected
GCP elements : MHRA inspection areas • Trial initiation, approvals and completion • Responsibilities of organisations and individuals • Recruitment and informed consent processes • Documentation and data quality • Safety reporting /pharmacovigilance
• Statutory Instrument 2004/1031 • Transposed European Clinical Trials Directive 2001/20/EC into UK Law from 1 May 2004 • Made amendments to the Medicines Act 1968 which regulated the supply of medicines for a clinical trial, but did not cover standards of conduct on a clinical trial SI 2004/1031 regulates the commencement and conduct of a clinical trial and the manufacture of medicinal products to be used (including placebo) Legislation: Medicines for Human Use (Clinical trials) Regulations 2004
• The second EU Directive clarified and extends the first • Major areas of change included: • - Duties can be delegated, but not responsibilities • - New requirements on sponsor and investigators in relation to Trial Documentation • - Notification of serious breaches • Statutory Instrument 2006/1928 • Transposed European Clinical Trials Directive 2005/28/EC into UK Law from 29 August 2006 • Makes amendments to the Medicines for Human Use (Clinical Trials) Regulations 2004 European Clinical Trials Directive 2005/28/EC
• There have also been subsequent Statutory Instruments which govern the conduct of clinical research in the UK. • The Statutory Instruments are: • 2004/1031 (1 May 2004) – EU Directive 2001/20/EC transposed into law • 2006/1928 (29 August 2006) – EU Directive 2005/28/EC transposed into law • 2006/2984 (12 December 2006) – A&E trials without consent for adults without • capacity • 2008/941 (1 May 2008) – Research Ethics Committee membership and approval • 2009/1164 (8 May 2009) – Urgent safety measures • 2010/1882 (19 August 2010) – Advanced Therapy Medicinal Products • All are available on the MHRA website • www.mhra.gov.uk Other UK Regulations
• Researchers work within other guidelines and laws, including • Data Protection Act (1998) • Protection of Children Act (1999) • Mental Capacity Act (2005) • Human Tissue Act (2004) • Equality and Diversity Legislation • Freedom of Information Act (2000) • Welsh Language Act 1993/ 2011 • Health Board Policies In addition …
DRUGS REGULATORY SYSTEM IN INDIA 53
 Drugs and Health is in concurrent list of Indian Constitution It is governed by both Centre and State Governments under the Drugs & Cosmetics Act, 1940. MAIN BODIES:  Central Drug Standard Control Organization (CDSCO)  Ministry Of Health & Family Welfare (MHFW)  Indian Council Of Medical Research (ICMR)  Indian Pharmaceutical Association (IPA)  Drug Technical Advisory Board (DTAB)  Central Drug Testing Laboratory (CDTL)  Indian Pharmacopoeia Commission (IPC)  National Pharmaceutical Pricing Authority (NPPA) 54
55 Functions undertaken by Central Government  Statutory function 1. Laying down standards of drugs, cosmetics, diagnostics and devices. 2. Laying down regulatory measures, amendments to Acts and Rules. 3. To regulate market authorization of new drugs. 4. To regulate clinical research in India 5. To approve licenses to manufacture certain categories of drugs as Central Licence Approving Authority i.e. for Blood Banks, Large Volume Parenterals and Vaccines & Sera. 6. To regulate the standards of imported drugs. 7. Work relating to the Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee (DCC). 8. Testing of drugs by Central Drugs Labs. 9. Publication of Indian Pharmacopoeia.
Regulations: For conducting CT in India • Permission is required from the DCGI for conducting CT phase 1-4. • Also for BABE studies • DD with in India/outside India • The application for permission to initiate a specific phase of CT include • Investigators Brochure • Data: Pharmacological/kinetic/toxicological/clinical/therapeutic rationale • Proposed trial protocol, case report form, informed consents, investigator undertaking, investigators CV • Regulatory status in other countries.
• If drug is developed in India, approval by ICMR is also required. • Guidelines for CT in India are based on ICH- GCP. • Lab used for studies sd be GMP and GLP approved.
• Ministry of Health and Family Welfare DGHS (Directorate General of Health Services) CDSCO DCGI INDIA – WELL DEFINED DRUG REGULATORY SYSTEM Govt. of India DTAB  Enforcement & GMP audit Div  Quality Control Division – CDTL  Registration Div  New Drug Div Pharmacovigilance Trainings 58
APPROVAL OF INVESTIGATIONAL NEW DRUG (IND) 59
61 61
62 62
Central Drugs Standard Control Organization • Organization Directorate General of Health Services Ministry of Health and Family Welfare, Government of India, FDA Bhavan, ITO, Kotla Road, New Delhi -110002 Phone: 91-11-23236975 / 23236971Fax: 91- 11-23236973E-Mail:- dci@nb.nic.in
Dr. Gyanendra Nath Singh M. Pharm., Ph.D., M.B.A. (U K) Drug Controller General of India
Approval of Biologics • CDSCO AND DCGI • Other than that Genetic engineering approval council Recombinant DNA advisory committee Review committee on genetic manipulation Institutional biosafety committee State biosafety coordination committee District level committee • National Biotechnology ACT 2008
Approval of medical devices • CDSCO • By notification SO1468 (2005). • The notification declares 10 categories of sterile devices to be considered as drugs under section 3 (b) of D&C act. These are cardiac stents, catherters, bone cement, heart valves, scalp vein sets, orthopaedic implants, cannulae intraocular lenses. • Separate committees for evaluation of these..
Regulation of Clinical trials • Schedule Y of D&C act • GCP • Guidelines for biomedical research on human participants, ICMR, 2006. • Guidance on clinical trial inspection, CDSCO • Guidance on submission of CT Applications for evaluating safety and efficacy. • Guidelines on BABE studies, CDESCO • Guidelines on GCLP
Data Monitoring Committee • Sponsorer must establish a data monitoring committee or data safety committee. • They assess the progress of a CT, data safety, efficacy endpoints at predetermined endpoints. They also recommend whether to continue/modify or stop the trial.
CTRI • Contains registered clinical trials in India
Regulation regarding transport • Committee on the transport of dangerous goods. • Committee of the United Nations Economic and Social council. • In india, ICMR has issued the guidelines on transfer of human development of commercial products.
74 CENTRAL LICENSING
75 National Institute of Health and Family Welfare (NIHFW) NIHFW is an Apex Technical Institute, funded by Ministry of Health and Family Welfare, for promotion of health and family welfare programmers in the country through education, training, research, evaluation, consultancy and specialized services. The NIHFW was established on March 9, 1977 by a merger of the National Institute of Health Administration and Education (NIHAE) with the National Institute of Family Planning (NIFP).
76 DRUG TECHNICALADVISORY BOARD (DTAB)  The Central Government constitute a Board (to be called the Drugs Technical Advisory Board) to advise the Central Government and the State Governments on technical matters arising out of the administration of D&C, Act 1940 The Board shall consist of the following members, 18 Members 10 ex-officio Members 5 Nominated Members 5 Elected Members
77 CENTRAL DRUG TESTING LABORATORY (CDTL)  The central drug laboratory, Kolkata is national statutory laboratory of the government of India for quality control of drug and cosmetic and established under the D&C act ,1940.  Oldest quality control laboratory of the drug control authorities in India.  Function under the director general of Health Services in the Ministry of Health and Family Welfare.

More Related Content

PPT
Regulation in clinical trial, Schedule Y and recent amendments
byDr. Siddhartha Dutta
 
PPTX
Regulation Governing Clinical Trials In India,USA and Europe.
byKapilKumar198
 
PPTX
clinical trial application in india
byRohit K.
 
PDF
CDSCO Regulatory Authority.pdf
byPrachi Pandey
 
PDF
Clinical Studies -- Overview of FDA Regulation
byMichael Swit
 
DOCX
MCQ on IMPD and IB
byArif Nadaf
 
PPTX
Origin and Principle of ICH(GCP) R2.pptx
byAkhilesh Tapase
 
PPTX
Regulation of drug sector in India
bySharath Gowda
 
Regulation in clinical trial, Schedule Y and recent amendments
byDr. Siddhartha Dutta
 
Regulation Governing Clinical Trials In India,USA and Europe.
byKapilKumar198
 
clinical trial application in india
byRohit K.
 
CDSCO Regulatory Authority.pdf
byPrachi Pandey
 
Clinical Studies -- Overview of FDA Regulation
byMichael Swit
 
MCQ on IMPD and IB
byArif Nadaf
 
Origin and Principle of ICH(GCP) R2.pptx
byAkhilesh Tapase
 
Regulation of drug sector in India
bySharath Gowda
 

What's hot

PDF
CLINICAL TRIAL PROTOCOL
byJayvantika Raulji
 
PPT
Schedule y
byMalla Reddy College of Pharmacy
 
PPTX
New drugs and Clinical Trials Rule in india 2019
byArya V Devi
 
PPTX
Good clinical practices(GCP)
byFardan Qadeer
 
PPTX
Clinical trail team ( stake holders )
byIrene Vadakkan
 
PPTX
Introduction to clinical research
byPradeep H
 
PPTX
Clinical research protocol
byPuneshwar Keshari
 
PPTX
Turacoz - Clinical Study Report
byTuracoz Healthcare Solutions
 
PPT
Clinical Trials Introduction
bybiinoida
 
PPTX
Ndct rule 2019 (manisha)
byManishaChauhan86
 
PPTX
Cdsco ppt
byNikhat Sheikh
 
PPT
Schedule Y
bykamalakar ambati
 
PPTX
ICH GCP
bySuman Baishnab
 
PPTX
Clinical trial monitoring
byDr. Ashish singh Parihar
 
PPTX
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
byClinosolIndia
 
PPTX
ICH GCP guidelines
byrx_sonali
 
PPTX
Informed consent process
byDeveraneniVinay
 
PPTX
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
by𝐌𝐫. 𝐑𝐚𝐡𝐮𝐥 𝐏𝐚𝐥*
 
PPT
Who art & med dra
byPlessan Joy
 
PPTX
Institutional review board by akshdeep sharma
byAkshdeep Sharma
 
CLINICAL TRIAL PROTOCOL
byJayvantika Raulji
 
Schedule y
byMalla Reddy College of Pharmacy
 
New drugs and Clinical Trials Rule in india 2019
byArya V Devi
 
Good clinical practices(GCP)
byFardan Qadeer
 
Clinical trail team ( stake holders )
byIrene Vadakkan
 
Introduction to clinical research
byPradeep H
 
Clinical research protocol
byPuneshwar Keshari
 
Turacoz - Clinical Study Report
byTuracoz Healthcare Solutions
 
Clinical Trials Introduction
bybiinoida
 
Ndct rule 2019 (manisha)
byManishaChauhan86
 
Cdsco ppt
byNikhat Sheikh
 
Schedule Y
bykamalakar ambati
 
ICH GCP
bySuman Baishnab
 
Clinical trial monitoring
byDr. Ashish singh Parihar
 
Institutional Review Board (IRB)/ Independent Ethics committee (IEC)
byClinosolIndia
 
ICH GCP guidelines
byrx_sonali
 
Informed consent process
byDeveraneniVinay
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
by𝐌𝐫. 𝐑𝐚𝐡𝐮𝐥 𝐏𝐚𝐥*
 
Who art & med dra
byPlessan Joy
 
Institutional review board by akshdeep sharma
byAkshdeep Sharma
 

Similar to Regulatory agencies

PPTX
Regulatory requirement for drug approval
byKahnu charan panigrahi
 
PPTX
Regulatory requirements for drug approval
byNamdeo Shinde
 
PPTX
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
byAartiPal23
 
PPTX
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
byClinosolIndia
 
PPTX
clinical trial aplications & regulatory bodies along with ICH guidelines
byDheeraj Saini
 
PPTX
Drug approval process
byLitashaGandhi
 
PPTX
Overview regulatory environment in usa,europe,india
byshabana parveen
 
PPT
Regulations, guidelines & ethics in clinical research
byDr. Harisha S
 
PPTX
Global Subbmission of IND, NDA, ANDA
byMaruthi.N
 
PPT
Schedule y -_priti_gupta
byPriti Gupta
 
PPTX
New Drug Development Process
byAvinash Kumar Chirimalla
 
PPTX
Schedule Y-2019
byDevang Rana
 
PPT
2003
bydijojohn
 
PPTX
Veena Sanjay Katoriya
byVEENA18
 
PPTX
Overview of Biopharmaceuticals -basics for students
bysatheeshpinkworld
 
PDF
FDA 2013 Clinical Investigator Training Course: FDA Structure and Mandate
byMedicReS
 
PPTX
What is clinical research? Why to do it?
byvsharma1087
 
PPT
2. regulations overview
byDr. Harisha S
 
PPTX
Investaigational drugs
bySultan Alharbi
 
PPT
Good clinical practices tutorial-june-21-09 shehnaz-v7.0
byShehnaz Vakharia
 
Regulatory requirement for drug approval
byKahnu charan panigrahi
 
Regulatory requirements for drug approval
byNamdeo Shinde
 
ICH-GCP (Aarti pal).pptx M PHARMACY Regulatory perspective of clinical trials
byAartiPal23
 
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
byClinosolIndia
 
clinical trial aplications & regulatory bodies along with ICH guidelines
byDheeraj Saini
 
Drug approval process
byLitashaGandhi
 
Overview regulatory environment in usa,europe,india
byshabana parveen
 
Regulations, guidelines & ethics in clinical research
byDr. Harisha S
 
Global Subbmission of IND, NDA, ANDA
byMaruthi.N
 
Schedule y -_priti_gupta
byPriti Gupta
 
New Drug Development Process
byAvinash Kumar Chirimalla
 
Schedule Y-2019
byDevang Rana
 
2003
bydijojohn
 
Veena Sanjay Katoriya
byVEENA18
 
Overview of Biopharmaceuticals -basics for students
bysatheeshpinkworld
 
FDA 2013 Clinical Investigator Training Course: FDA Structure and Mandate
byMedicReS
 
What is clinical research? Why to do it?
byvsharma1087
 
2. regulations overview
byDr. Harisha S
 
Investaigational drugs
bySultan Alharbi
 
Good clinical practices tutorial-june-21-09 shehnaz-v7.0
byShehnaz Vakharia
 

More from Urmila Aswar

PPTX
OECD Guidelines
byUrmila Aswar
 
PPTX
OECD Guidelines
byUrmila Aswar
 
PPTX
Phases-of-Drug-Discovery-A-Timeline-and-Cost-Analysis.pptx
byUrmila Aswar
 
PDF
Cinical trial protocol writing
byUrmila Aswar
 
PDF
Randomisation techniques
byUrmila Aswar
 
PDF
Case studies patent
byUrmila Aswar
 
PDF
Patent search
byUrmila Aswar
 
PDF
Intellectual property appellate board
byUrmila Aswar
 
PDF
Depression
byUrmila Aswar
 
PDF
Pathophysiology of Schizophrenia
byUrmila Aswar
 
PDF
Parkinson's disease and alzheimer's disease
byUrmila Aswar
 
PPT
Hypolipidemic drugs.ppt
byUrmila Aswar
 
PDF
Hypertension
byUrmila Aswar
 
PDF
Lipid metabolism and hypolipedemic drugs
byUrmila Aswar
 
PDF
Pathophysiology of Leprosy
byUrmila Aswar
 
PDF
Pathophysiology of Coronary artery d isease
byUrmila Aswar
 
PPTX
Peptic ulcer.pptx
byUrmila Aswar
 
PPTX
Hypertension and treatment.pptx
byUrmila Aswar
 
PDF
Malaria
byUrmila Aswar
 
PDF
Arrythmias
byUrmila Aswar
 
OECD Guidelines
byUrmila Aswar
 
OECD Guidelines
byUrmila Aswar
 
Phases-of-Drug-Discovery-A-Timeline-and-Cost-Analysis.pptx
byUrmila Aswar
 
Cinical trial protocol writing
byUrmila Aswar
 
Randomisation techniques
byUrmila Aswar
 
Case studies patent
byUrmila Aswar
 
Patent search
byUrmila Aswar
 
Intellectual property appellate board
byUrmila Aswar
 
Depression
byUrmila Aswar
 
Pathophysiology of Schizophrenia
byUrmila Aswar
 
Parkinson's disease and alzheimer's disease
byUrmila Aswar
 
Hypolipidemic drugs.ppt
byUrmila Aswar
 
Hypertension
byUrmila Aswar
 
Lipid metabolism and hypolipedemic drugs
byUrmila Aswar
 
Pathophysiology of Leprosy
byUrmila Aswar
 
Pathophysiology of Coronary artery d isease
byUrmila Aswar
 
Peptic ulcer.pptx
byUrmila Aswar
 
Hypertension and treatment.pptx
byUrmila Aswar
 
Malaria
byUrmila Aswar
 
Arrythmias
byUrmila Aswar
 

Recently uploaded

PPTX
(EL FILIBUSTERISMO BRIEF HISTORY...)pptx
byangelkatrine3
 
PDF
WisdomTooths Consultancy Fresh O Kiosk Mobile App
bytomrick
 
PDF
WisdomTooths Consultancy Case Study Ayurvedic Kolkata
bytomrick
 
PDF
How to Buy Verified RedotPay Account.pdf
bya32sop3orzibld4x34e4
 
PDF
CHAPTER 2 POSITIONING AND BRANDING of company
byUtsash Sarker
 
PDF
How to Verify Your PayPal Account in 2025.pdf
by5hb3cqye5o4j0o2dne3x
 
PDF
TikTok Shop Seller Center _ Manage Products, Orders ... (1).pdf
bydubivgplc4wloha4rxsm
 
PDF
How to Buy Verified Stripe Accounts,in 2025.pdf
bydubivgplc4wloha4rxsm
 
PDF
Buy Verified Paypal Accounts : Personal & Business Accounts.pdf
byHow to Safely Buying Verified Cash App Accounts: A Comprehensive Guide
 
PDF
Top 5 Places to Buy Aged LinkedIn Accounts and Should ....pdf
by5hb3cqye5o4j0o2dne3x
 
PDF
How To Safely Buy Instagram Accounts In 2025.pdf
bydubivgplc4wloha4rxsm
 
PDF
How And Where To Buy LinkedIn Accounts_ New 2025 ... (1).pdf
byusatrustacc5
 
PDF
How do I subscribe to Snapchat in usa 2025+_.pdf
bydubivgplc4wloha4rxsm
 
PDF
Where to Buy LinkedIn Accounts_ [12 Best Sites] (2).pdf
bydubivgplc4wloha4rxsm
 
PDF
Where to Buy LinkedIn Accounts_ [12 Best Sites] (3).pdf
bya32sop3orzibld4x34e4
 
PPTX
Thermal Energy International Presentation - 2025 AGM
byMarketing847413
 
DOCX
Trusted Top Site to Buy Verified PayPal Account Online Finance.docx
byCan I buy a verified Wise account?
 
DOCX
How Do I Buy Verified Wise Accounts for Personal Use.docx
byCan I buy a verified Wise account?
 
PDF
Lion One Corporate Presentation November 2025
byAdnet Communications
 
PDF
Joseph Heiman New Jersey - Passionate About Finance
byJoseph Heiman New Jersey
 
(EL FILIBUSTERISMO BRIEF HISTORY...)pptx
byangelkatrine3
 
WisdomTooths Consultancy Fresh O Kiosk Mobile App
bytomrick
 
WisdomTooths Consultancy Case Study Ayurvedic Kolkata
bytomrick
 
How to Buy Verified RedotPay Account.pdf
bya32sop3orzibld4x34e4
 
CHAPTER 2 POSITIONING AND BRANDING of company
byUtsash Sarker
 
How to Verify Your PayPal Account in 2025.pdf
by5hb3cqye5o4j0o2dne3x
 
TikTok Shop Seller Center _ Manage Products, Orders ... (1).pdf
bydubivgplc4wloha4rxsm
 
How to Buy Verified Stripe Accounts,in 2025.pdf
bydubivgplc4wloha4rxsm
 
Buy Verified Paypal Accounts : Personal & Business Accounts.pdf
byHow to Safely Buying Verified Cash App Accounts: A Comprehensive Guide
 
Top 5 Places to Buy Aged LinkedIn Accounts and Should ....pdf
by5hb3cqye5o4j0o2dne3x
 
How To Safely Buy Instagram Accounts In 2025.pdf
bydubivgplc4wloha4rxsm
 
How And Where To Buy LinkedIn Accounts_ New 2025 ... (1).pdf
byusatrustacc5
 
How do I subscribe to Snapchat in usa 2025+_.pdf
bydubivgplc4wloha4rxsm
 
Where to Buy LinkedIn Accounts_ [12 Best Sites] (2).pdf
bydubivgplc4wloha4rxsm
 
Where to Buy LinkedIn Accounts_ [12 Best Sites] (3).pdf
bya32sop3orzibld4x34e4
 
Thermal Energy International Presentation - 2025 AGM
byMarketing847413
 
Trusted Top Site to Buy Verified PayPal Account Online Finance.docx
byCan I buy a verified Wise account?
 
How Do I Buy Verified Wise Accounts for Personal Use.docx
byCan I buy a verified Wise account?
 
Lion One Corporate Presentation November 2025
byAdnet Communications
 
Joseph Heiman New Jersey - Passionate About Finance
byJoseph Heiman New Jersey
 

Regulatory agencies

  • 1.
    Clinical Trials regulations DrUrmila M. Aswar Department of Pharmacology, SIOP, Narhe
  • 2.
    Investigational New DrugApplication • Current Federal law requires that a drug be approved for marketing application before it is transported or distributed across state lines. • But in case of investigational drug, it is required by clinical investigators in many states. • IND is an exemption.
  • 3.
    • FDA's rolein the development of a new drug begins when the drug's sponsor (usually the manufacturer or potential marketer) having screened the new molecule for pharmacological activity and acute toxicity potential in animals, wants to test its diagnostic or therapeutic potential in humans. At that point, the molecule changes in legal status under the Federal Food, Drug, and Cosmetic Act and becomes a new drug subject to specific requirements of the drug regulatory system.
  • 4.
    Animal Pharmacology andToxicology Studies
  • 5.
    Manufacturing Information Composition, manufacturer,stability, and controls used for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug. Lic form-29 is taken for mfg of new drug
  • 6.
    Clinical Protocols andInvestigator Information • Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. • Information on the qualifications of clinical trial team. • Informed consent from the research subjects, • to obtain review of the study by an institutional review board (IRB), • Adherence to the investigational new drug regulations.
  • 7.
    Review by FDA •Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA (DCGI/CDSCO) has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.
  • 8.
    Summary • An applicationto conduct clinical trials in India should be submitted along with the data of chemistry, manufacturing, control and animal studies to DCGI. The date regarding the trial protocol, investigator's brochures, and informed consent documents should also be attached. A copy of the application must be submitted to the ethical committee and the clinical trials are conducted only after approval of DCGI and ethical committee. To determine the maximum tolerated dose in humans, adverse reactions, etc.
  • 9.
    New Drug Application •The new drug registration (using form no. 44 along with full pre-clinical and clinical testing information) is applied after the completion of clinical trials. • The comprehensive information on the marketing status of the drug in other countries is also required other than the information on safety and efficacy. • The information regarding the prescription, samples and testing protocols, product monograph, labels, and cartons must also be submitted. • Schedule Y of D&C act, provides the guidelines and requirements for clinical trials. • The application can be reviewed in a range of about 12- 18 months
  • 10.
    Regulatory bodies inWorld • USA: FDA, Dept of health and human services • Canada: Health Canada • UK: Medicines and Healthcare products regulatory agency (MHRA) • EU: European Medicines Agency (EMEA) • Japan: Pharmaceutical and Medical Devices agencies (PMDA) • India:
  • 11.
    Regulating bodies inIndia • The Drug and Cosmetic Act 1940 and Rules 1945 were passed by the India's parliament to regulate the import, manufacture, distribution and sale of drugs and cosmetics. • The Central Drugs Standard Control Organization (CDSCO), • The Drugs Controller General (India) [DCGI] was established.
  • 12.
  • 13.
    Regulatory requirements forclinical trials Before starting trial • Consent of investigator • Approval by IRB..approval of protocol, site, • Approval from ICMR in case of new molecules developed in India • Informed consent • Insurance cover for trial related injury
  • 14.
    During the conduct •Compliance with the trial protocol • Reporting protocol violations to EC • Seek approval for protocol amendments • Adherence to GCP • Record all adverse effects • Record of all serious adverse effects to sponsor in 24 hr • Notification of fatal adv effect to RB • Review the progress of results of study • Send periodic status of study.
  • 15.
    Post trial requirement •Site close out • Check investigational product utilization • Analyze the data using statistical softwares • Forward the report from investigator to EC • Seek new drug approval. • Prepare and submit the prescribing information for ND to the authorities
  • 16.
    Newly approved drugs •Gilotrif (afatinib) Tablets: for lung cancer Boehringer Ingelheim Pharmaceuticals • Khedezla (desvenlafaxine): for depression Osmotica Pharmaceutical Corp.
  • 17.
  • 18.
  • 19.
    • Clinical trials:World wide • Follow ICH/WHO, GCP provides universal standards • US, Canada, EU, Japan, Australia and India
  • 21.
    USFDA: Achievements inClinical Research (1975-2000) • Ethical Principles and Infrastructure (IRBs) • Evidence-Based Decision-Making – Safety; Efficacy • Standards of Research Conduct (GCP) • International Harmonization • Quality Improvement
  • 22.
    Why so muchstrict: A Change in Clinical Trials • More clinical investigators • More studies • More participation of vulnerable populations – Children, Elderly, Ethnic Groups, etc. • More “outsourcing” (CRO’s, SMO’s) • New technologies • Global expansion – Countries/areas new to GCP
  • 23.
    CT Disasters inhistory: A lesson • May 1999: NY Times, “Research for Hire. A Doctor’s Drug Studies Turn into Fraud” • September 1999: Death in gene therapy trial • December 2000: Washington Post series “The Body Hunters” • June 2001: Death in lung physiology trial
  • 25.
    FDA’s Mission • FDAhas a broad public protection mission Ensure the safe use of regulated products that are themselves safe and efficacious Approvals: Based on complete and accurate information from well-designed, ethically- conducted, and well-monitored clinical research
  • 26.
    FDA’s Mission inClinical Research • Ensure Implementation of Good Clinical Practice (GCP) Standards – GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects – GCP embraces trial objectives, trial design, study oversight, data collection and quality assurance, study analysis, as well as human subject protection in studies that support product applications
  • 27.
    Good Clinical Practice •GCP is most fundamentally a System of Shared Responsibilities –Clinical Investigators –Institutions/Institutional Review Boards –Industry (Sponsors/Monitors) –Government Regulators
  • 28.
    FDA: Regulations • Federalfood, drug and cosmetic act, 1938 • Orphan drug act 1983, • Prescription drug user fee act, 1992 (PDUFA). • Food and drug modernization act 1997, (FDAMA)
  • 29.
    3 approaches fortreating serious diseases • Fast track: to get important new drug to the patient ealier. • For no therapy/ superior new drug. • Accelerated approval: allows earlier approvals of drugs to treat serious diseases or fills an unmet medical need based on a surrogate endpoint. • S.endpoint means a lab test or a physical sign or survival. • Post marketing trials become important. • Continue or remove • Priority review: the drugs that offer major advantage in the treatment or provide a treatment where no adequate therapy exists. • Review time is reduced.
  • 30.
    Federal food, drugand cosmetic act, 1938 • Basic food and drug law in the US • Food are pure and safe to eat • Drugs and devices are safe to use • Cosmetics are safe and made from appropriate ingredients.
  • 31.
    Code for federalregulations (CFR) • The CFR is divided into 50 titles • SECTION 21 OF CFR –regulations related to food and drugs. • Part of CFR 21 give details of IND (312), NDA (314), orphan drugs (316)
  • 33.
    Center for BiologicsEvaluation and Research (CBER) • Section 505 of FD & C provide that no person can market a drug without filling IND. • Dept of health and human services of FDA protects the rights of human in Clinical Trial. • The CBER is one of six main centers for the U.S. Food and Drug Administration, which is a part of the U.S. Department of Health and Human Services. • CBER is responsible for assuring the safety, purity, potency, and effectiveness of biologics and related products (such as vaccines live biotherapeutics (probiotics), blood products, and cell, tissue, and gene therapies).
  • 34.
    Center for DrugsEvaluation and Research (CDER) • The center reviews applications for new and generic pharmaceuticals, manages US current Good Manufacturing Practice (cGMP) regulations for pharmaceutical manufacturing, determines which medications require a medical prescription, monitors advertising of approved medications, and collects and analyzes safety data about pharmaceuticals that are already on the market. • CDER reviews New Drug Applications to ensure that the drugs are safe and effective. Its primary objective is to ensure that all prescription and OTC medications are safe and effective when used as directed.
  • 35.
    Bioresearch Monitoring Program •FDA's Bioresearch Monitoring (BIMO) program is a comprehensive program of on-site inspections and data audits designed to monitor all aspects of the conduct and reporting of FDA regulated research. • It assure the quality and integrity of data submitted to the agency in support of new product approvals. • It provide for protection of the rights and welfare of the thousands of human subjects involved in FDA regulated research. • It has become a cornerstone of the FDA preapproval process for new medicines, medical devices, food and color additives and veterinary products introduced to the U.S. consumer.
  • 36.
    • Post Ranbaxy,Wockhardt faces a hit as US FDA bans imports over quality concerns ET Bureau May 24, 2013 • The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS)
  • 37.
    Regulations-UK/EU • Drugs arelicensed for use in the UK with a European license or a national license. They are licensed through European Medicines Agency (EMEA) for Europe wide license and from Medicine and healthcare products regulatory agency (MHRA) for UK license. EMEA, Committee for orphan medicinal products (COMP): orphan drugs: 5/10,000
  • 40.
    Centralized system inEMEA • Drugs for AIDS • NEURODEGENRATIVE DISEASES • CANCER • DIABETES • ORPHAN DRUGS
  • 41.
    Decentralized system inEMEA • Other than the listed • Apply for more than one country of EU • With review of 1 country can be licensed in other.
  • 42.
    • Prior to2004 the standards were guidelines and dual standards existed • For the first time ethical and scientific standards for the set up, and conduct of clinical research involving human subjects receiving investigational medicinal products, became subject to law CLINICAL TRIAL REGULATIONS
  • 43.
    • EU Directivesare legislation issued by the European Union defining an outcome or change that is binding for each member state • EU Directives must be transposed into law for each member state to become law in that country • In the UK this is achieved by the introduction of a Statutory Instrument named within an Act of Parliament, which then becomes the law European Directives & UK Laws
  • 44.
    EU Clinical TrialsDirective 2001/20/EC EU GCP Directive 2005/28/EC EU Legislation UK Legislation Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 1031) Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (SI 1928) Amendment 2006 (SI 2964) Amendment 2008 (SI 941) Amendment 2009 (SI 1164) ‘Guidance’ EC Commission Eudralex – Volume 10 Clinical Trial guidelines ICH GCP Topic E6 – Good Clinical Practice Organisation/Sponsor SOPs Research Governance Framework for Health and Social Care • Amendment 2010 (SI 1882)
  • 45.
    • Introduced toensure that everyone follows the same GCP standards • Clarified and standardised practice for the safety of the subject and the quality of the data. • Major areas of change included: • - The ethics review system came under the law • - Each member state had to appoint a Competent Authority (MHRA in UK) • - Strengthened consent for vulnerable groups • - Amendments required to follow a process • - Additional safety reporting requirements • - All results have to be made available even if negative findings were found European Clinical Trials Directive 2001/20/EC
  • 46.
    GCP principles area standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are protected
  • 47.
    GCP elements :MHRA inspection areas • Trial initiation, approvals and completion • Responsibilities of organisations and individuals • Recruitment and informed consent processes • Documentation and data quality • Safety reporting /pharmacovigilance
  • 48.
    • Statutory Instrument2004/1031 • Transposed European Clinical Trials Directive 2001/20/EC into UK Law from 1 May 2004 • Made amendments to the Medicines Act 1968 which regulated the supply of medicines for a clinical trial, but did not cover standards of conduct on a clinical trial SI 2004/1031 regulates the commencement and conduct of a clinical trial and the manufacture of medicinal products to be used (including placebo) Legislation: Medicines for Human Use (Clinical trials) Regulations 2004
  • 49.
    • The secondEU Directive clarified and extends the first • Major areas of change included: • - Duties can be delegated, but not responsibilities • - New requirements on sponsor and investigators in relation to Trial Documentation • - Notification of serious breaches • Statutory Instrument 2006/1928 • Transposed European Clinical Trials Directive 2005/28/EC into UK Law from 29 August 2006 • Makes amendments to the Medicines for Human Use (Clinical Trials) Regulations 2004 European Clinical Trials Directive 2005/28/EC
  • 51.
    • There havealso been subsequent Statutory Instruments which govern the conduct of clinical research in the UK. • The Statutory Instruments are: • 2004/1031 (1 May 2004) – EU Directive 2001/20/EC transposed into law • 2006/1928 (29 August 2006) – EU Directive 2005/28/EC transposed into law • 2006/2984 (12 December 2006) – A&E trials without consent for adults without • capacity • 2008/941 (1 May 2008) – Research Ethics Committee membership and approval • 2009/1164 (8 May 2009) – Urgent safety measures • 2010/1882 (19 August 2010) – Advanced Therapy Medicinal Products • All are available on the MHRA website • www.mhra.gov.uk Other UK Regulations
  • 52.
    • Researchers workwithin other guidelines and laws, including • Data Protection Act (1998) • Protection of Children Act (1999) • Mental Capacity Act (2005) • Human Tissue Act (2004) • Equality and Diversity Legislation • Freedom of Information Act (2000) • Welsh Language Act 1993/ 2011 • Health Board Policies In addition …
  • 53.
  • 54.
     Drugs andHealth is in concurrent list of Indian Constitution It is governed by both Centre and State Governments under the Drugs & Cosmetics Act, 1940. MAIN BODIES:  Central Drug Standard Control Organization (CDSCO)  Ministry Of Health & Family Welfare (MHFW)  Indian Council Of Medical Research (ICMR)  Indian Pharmaceutical Association (IPA)  Drug Technical Advisory Board (DTAB)  Central Drug Testing Laboratory (CDTL)  Indian Pharmacopoeia Commission (IPC)  National Pharmaceutical Pricing Authority (NPPA) 54
  • 55.
    55 Functions undertaken by CentralGovernment  Statutory function 1. Laying down standards of drugs, cosmetics, diagnostics and devices. 2. Laying down regulatory measures, amendments to Acts and Rules. 3. To regulate market authorization of new drugs. 4. To regulate clinical research in India 5. To approve licenses to manufacture certain categories of drugs as Central Licence Approving Authority i.e. for Blood Banks, Large Volume Parenterals and Vaccines & Sera. 6. To regulate the standards of imported drugs. 7. Work relating to the Drugs Technical Advisory Board (DTAB) and Drugs Consultative Committee (DCC). 8. Testing of drugs by Central Drugs Labs. 9. Publication of Indian Pharmacopoeia.
  • 56.
    Regulations: For conductingCT in India • Permission is required from the DCGI for conducting CT phase 1-4. • Also for BABE studies • DD with in India/outside India • The application for permission to initiate a specific phase of CT include • Investigators Brochure • Data: Pharmacological/kinetic/toxicological/clinical/therapeutic rationale • Proposed trial protocol, case report form, informed consents, investigator undertaking, investigators CV • Regulatory status in other countries.
  • 57.
    • If drugis developed in India, approval by ICMR is also required. • Guidelines for CT in India are based on ICH- GCP. • Lab used for studies sd be GMP and GLP approved.
  • 58.
    • Ministry ofHealth and Family Welfare DGHS (Directorate General of Health Services) CDSCO DCGI INDIA – WELL DEFINED DRUG REGULATORY SYSTEM Govt. of India DTAB  Enforcement & GMP audit Div  Quality Control Division – CDTL  Registration Div  New Drug Div Pharmacovigilance Trainings 58
  • 59.
    APPROVAL OF INVESTIGATIONALNEW DRUG (IND) 59
  • 61.
  • 62.
  • 63.
    Central Drugs StandardControl Organization • Organization Directorate General of Health Services Ministry of Health and Family Welfare, Government of India, FDA Bhavan, ITO, Kotla Road, New Delhi -110002 Phone: 91-11-23236975 / 23236971Fax: 91- 11-23236973E-Mail:- [email protected]
  • 64.
    Dr. Gyanendra NathSingh M. Pharm., Ph.D., M.B.A. (U K) Drug Controller General of India
  • 65.
    Approval of Biologics •CDSCO AND DCGI • Other than that Genetic engineering approval council Recombinant DNA advisory committee Review committee on genetic manipulation Institutional biosafety committee State biosafety coordination committee District level committee • National Biotechnology ACT 2008
  • 68.
    Approval of medicaldevices • CDSCO • By notification SO1468 (2005). • The notification declares 10 categories of sterile devices to be considered as drugs under section 3 (b) of D&C act. These are cardiac stents, catherters, bone cement, heart valves, scalp vein sets, orthopaedic implants, cannulae intraocular lenses. • Separate committees for evaluation of these..
  • 69.
    Regulation of Clinicaltrials • Schedule Y of D&C act • GCP • Guidelines for biomedical research on human participants, ICMR, 2006. • Guidance on clinical trial inspection, CDSCO • Guidance on submission of CT Applications for evaluating safety and efficacy. • Guidelines on BABE studies, CDESCO • Guidelines on GCLP
  • 70.
    Data Monitoring Committee •Sponsorer must establish a data monitoring committee or data safety committee. • They assess the progress of a CT, data safety, efficacy endpoints at predetermined endpoints. They also recommend whether to continue/modify or stop the trial.
  • 72.
    CTRI • Contains registeredclinical trials in India
  • 73.
    Regulation regarding transport •Committee on the transport of dangerous goods. • Committee of the United Nations Economic and Social council. • In india, ICMR has issued the guidelines on transfer of human development of commercial products.
  • 74.
  • 75.
    75 National Institute ofHealth and Family Welfare (NIHFW) NIHFW is an Apex Technical Institute, funded by Ministry of Health and Family Welfare, for promotion of health and family welfare programmers in the country through education, training, research, evaluation, consultancy and specialized services. The NIHFW was established on March 9, 1977 by a merger of the National Institute of Health Administration and Education (NIHAE) with the National Institute of Family Planning (NIFP).
  • 76.
    76 DRUG TECHNICALADVISORY BOARD (DTAB) The Central Government constitute a Board (to be called the Drugs Technical Advisory Board) to advise the Central Government and the State Governments on technical matters arising out of the administration of D&C, Act 1940 The Board shall consist of the following members, 18 Members 10 ex-officio Members 5 Nominated Members 5 Elected Members
  • 77.
    77 CENTRAL DRUG TESTINGLABORATORY (CDTL)  The central drug laboratory, Kolkata is national statutory laboratory of the government of India for quality control of drug and cosmetic and established under the D&C act ,1940.  Oldest quality control laboratory of the drug control authorities in India.  Function under the director general of Health Services in the Ministry of Health and Family Welfare.

Editor's Notes

  • #19 Ethical standards to protect people have been around for over 60 years